References
- Poulin Y, Lynde CW, Barber K, et al. Non-melanoma skin cancer in Canada chapter 3: management of actinic keratoses. J Cutan Med Surg. 2015;19(3):227–7.
- HAS. Transparency committee opinion: METVIXIA 168 mg. 2014.
- Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335–339.
- Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American academy of dermatology association and the society for investigative dermatology. J Am Acad Dermatol. 2006;55(3):490–500.
- HAS. Transparency committee opinion: METVIXIA 168 mg. 2017.
- Dermatologie Sfd. [Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. Guidelines]. Revue de stomatologie et de chirurgie maxillo-faciale. 2010;111(4):228–237.
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–2079.
- Calzavara-Pinton P, Haedersdal M, Barber K, et al. Structured expert consensus on actinic keratosis: treatment algorithm focusing on daylight PDT. J Cutan Med Surg. 2017;21(Suppl. 1):3S-16S. 1203475417702994.
- HAS. Avis de la Commission de la Transparence Ameluz. 2016.
- Girard C, Adamski H, Basset-Seguin N, et al. [Procedure for daylight methyl aminolevulinate photodynamic therapy to treat actinic keratoses]. Annales de dermatologie et de venereologie. 2016;143(4):257–263.
- Database O. OneKey Santé database – IQVIA. [cited 2019 Mar 21]. Available from: https://www.smartdataforlead.com/fichiers-prospection-btob/fichier-prospection-medicale-onekey/